onc Videos

Videos

Hyman Muss, MD, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

Videos

Delivering Effective End-of-Life Care for Patients With Breast Cancer

03/17/2023

Hyman Muss, MD, details his best practices for delivering effective end-of-life care for patients with breast cancer.

Hyman Muss, MD, details his best...

03/17/2023

Oncology

Benjamin Miron, MD, Fox Chase Cancer Center

Videos

A Treatment Plan for Advanced Urothelial Carcinoma With Spinal and Liver Metastasis

03/16/2023

Benjamin Miron, MD, discusses the course of treatment he would take for a patient with advanced urothelial carcinoma with spinal and liver metastasis.

Benjamin Miron, MD, discusses...

03/16/2023

Oncology

Kelly Hunt, MD, MD Anderson Cancer Center, Houston, TX

Videos

Axillary Reverse Mapping: Preventing Lymphedema Among Patients With Breast Cancer

03/16/2023

Kelly Hunt, MD, discusses the practice of axillary reverse mapping in the prevention of lymphedema for patients with breast cancer.

Kelly Hunt, MD, discusses the...

03/16/2023

Oncology

Alison Schram, MD, Memorial Sloan Kettering Cancer Center

Videos

Targeting Class II/III Alterations in BRAF Inhibitors

03/16/2023

At 2023 ESMO Targeted Anticancer Therapies Congress, Alison Schram, MD, discusses the class II/III alterations of BRAF inhibitors.

At 2023 ESMO Targeted Anticancer...

03/16/2023

Oncology

Videos

Metronomic Chemotherapy for Patients With Breast Cancer

03/16/2023

Dr Hyman Muss offers his insights on how metronomic chemotherapy can fit into the treatment paradigm for patients with breast cancer.

Dr Hyman Muss offers his...

03/16/2023

Oncology

Arielle Medford, MD, Dana-Farber Cancer Institute, Boston, MA

Videos

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab Chemotherapy for HER2-Positive Breast Cancer

03/14/2023

Arielle Medford, MD, outlines the steps she would take to treat a patient with ER-negative, PR-negative, HER2-positive breast cancer.

Arielle Medford, MD, outlines...

03/14/2023

Oncology

Videos

Benefit of AlloSCT for Patients With TP53 Mutations and Acute Myeloid Leukemia/Myelodysplastic Syndromes

03/13/2023

Koen W. van Besien, MD, recaps a debate in which he argued that patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and TP53 mutations should undergo allogeneic stem cell transplantation.

Koen W. van Besien, MD, recaps a...

03/13/2023

Oncology

Videos

No Improvement to Survival Outcomes With Pembrolizumab Plus Docetaxel for Castration-Resistant Prostate Cancer

03/10/2023

Daniel Petrylak, MD, discusses an abstract presented at 2023 ASCO Genitourinary Cancers Symposium, evaluating pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.

Daniel Petrylak, MD, discusses...

03/10/2023

Oncology

Wei Shen Tan, MD, PhD, and Ashish Kamat, MD, MBBS, MD Anderson Cancer Center

Videos

Bladder-Sparing Options for BCG-Unresponsive Bladder Cancer

03/08/2023

Drs Wei Shen Tan and Ashish Kamat discuss the treatment options for a patient who develops disease recurrence following treatment with BCG and who is unwilling to undergo radical cystectomy.

Drs Wei Shen Tan and Ashish...

03/08/2023

Oncology

Neeraj Agarwal, MD, Huntsman Cancer Institute

Videos

Talazoparib Plus Enzalutamide Improves PFS in Metastatic Castration-Resistant Prostate Cancer

03/08/2023

At the 2023 ASCO Genitourinary Cancers Symposium, Neeraj Agarwal, MD, presented results from a phase 3 trial evaluating enzalutamide plus talazoparib vs enzalutamide plus placebo for patients with metastatic castration-resistant prostate...

At the 2023 ASCO Genitourinary...

03/08/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology